How State Medicaid Programs Evaluate Interchangeability When Determining Mandatory Biosimilar Substitution and Preferred Drug List Placement

Biosimilar adoption in Medicaid rests on two related decisions. One is whether pharmacists can substitute an interchangeable biosimilar for its reference biologic without a prescriber’s approval. The other is how that biosimilar ranks on the state’s preferred drug list (PDL). Both choices depend on how state agencies interpret federal definitions of “interchangeability” under the Food, Drug, and Cosmetic Act and how that aligns with Medicaid Drug Rebate Program cost-control rules. Each state must balance clinical confidence, statutory authority, and fiscal responsibility when deciding whether substitution will be mandatory or optional.

Federal Definitions vs. State Authority

The Food and Drug Administration designates a biosimilar as “interchangeable” when it’s expected to produce the same clinical result as the reference product in any given patient, and alternating between them does not increase safety or efficacy risk. That designation allows, but doesn’t require, pharmacy-level substitution. Each state sets its own substitution rules, deciding how pharmacists apply interchangeability in practice for Medicaid and commercial coverage alike.

State Medicaid agencies usually reference FDA interchangeability when determining if substitution should be automatic. Some states allow it for any FDA‑designated product; others require explicit approval from the prescriber or a separate policy from the pharmacy board. The deciding factor is how each state translates federal regulatory authority into Medicaid benefit operations. That interpretation often shows up in plan guidance and PDL criteria rather than in statute.

How Committees Weigh Biosimilar Placement

Before a biosimilar lands on the PDL, the Medicaid agency’s Pharmacy and Therapeutics (P&T) committee reviews comparative clinical data. It looks at FDA labeling, published equivalence studies, and interchangeability status. If interchangeability is granted, the biosimilar is treated as clinically equivalent to the reference biologic, usually aligning with automatic substitution if the law allows. The committee then examines cost. Because rebates under the Medicaid Drug Rebate Program apply to both reference and biosimilar products, states assess net price after supplemental rebates to determine overall cost-effectiveness.

Interchangeability speeds favorable PDL placement. A biosimilar with that status often earns “preferred” designation more quickly, since substitution streamlines pharmacy processes and reduces provider paperwork. Without interchangeability, even clinically comparable products may still require prior authorization or remain non‑preferred until more switching data arrive. That distinction shapes what product Medicaid beneficiaries actually receive at the pharmacy counter.

Comparison of State Substitution Frameworks

Evaluation Dimension Mandatory Substitution States Conditional Substitution States
Authority reference FDA interchangeability automatically recognized Needs adoption by board of pharmacy or Medicaid directive
Prescriber override Allowed only if “dispense as written” noted Often requires prescriber consent or notification
PDL implication Biosimilars typically gain preferred status if cost advantage exists Biosimilars reviewed in formal cycles; no automatic preference
Rebate negotiation effect Higher substitution drives better supplemental rebates Negotiations slower due to limited utilization

This policy difference affects how quickly products move through utilization management. When substitution is mandatory, pharmacists dispense the interchangeable biosimilar unless the prescriber specifies the reference product. That reduces friction. Conditional states require prescriber confirmation before switching, introducing delays that can affect rebate outcomes and dispensing speed.

Program Integrity and Oversight

Processes for verifying provider intent resemble oversight used across other Medicaid and Marketplace operations. The Government Accountability Office (GAO) reported that CMS employs validation and consent steps to prevent unauthorized actions in plan management. As GAO noted, “In 2024, CMS implemented new procedures to better ensure agents and brokers obtain consumers’ consent prior to certain actions.” The principle is consistent: any benefit change needs verifiable consent. For pharmacies, the same idea applies, biosimilar substitution must match regulatory standards and the prescriber’s documented intent.

Some states mirror that level of control by adding verification steps, such as electronic confirmation before substitution. That extra documentation acts as a safeguard, ensuring change only occurs with explicit consent. The aim matches CMS’s own oversight of benefit changes: prevent unapproved switches and preserve accuracy in plan actions. Medicaid agencies rely on system edits, board rules, and claims validation for the same reason.

Balancing Financial and Clinical Decisions

States rarely view interchangeability on its own. PDL decisions blend drug cost, clinical performance, administration needs, biosimilar availability, and rebate potential. Interchangeability shapes those variables. A biosimilar that can be substituted automatically simplifies rebate budgeting and drives utilization, attractive to fiscal planners. Without interchangeability, states often keep the reference drug preferred or use step therapy to manage transitions, delaying broader uptake until more evidence is available.

All states follow the same Medicaid mandate: ensure clinically appropriate access while meeting federal rebate requirements. Interchangeability creates the legal space for substitution; budget design then determines the actual scope of use. When committees assess new biosimilars, those two forces, FDA designation and financial impact, define the conversation.

Day‑to‑Day Effects for Pharmacists and Patients

State rules tell pharmacies how dispensing systems handle biosimilars. In mandatory substitution states, claims systems automatically swap in the interchangeable product unless “dispense as written” is entered. Under conditional substitution, pharmacists must confirm prescriber approval first. For patients, that difference shows up through therapy continuity and copay outcomes. Although plan designs vary, widespread biosimilar substitution tends to narrow cost gaps for Medicaid members because both reference and biosimilar products get federal rebates.

Prescribers still control ultimate choice, but the administrative route diverges. In mandatory systems, they must state medical necessity for the original biologic. In conditional ones, default authority stays with them and substitution requires explicit approval. Each approach reflects how a state weighs provider control against predictability in spending.

Interchangeability as a Policy Signal

The FDA defines interchangeability through science. State Medicaid programs interpret it as a policy signal, guiding contracts, provider confidence, and communication with patients. Those that pair interchangeability with mandatory substitution lean on FDA evaluation to streamline rules. Others hold back, citing the need for more evidence or legal constraints. Either way, interchangeability anchors the discussion, a scientific measure translated into state‑specific financial and operational terms that shape how biologic drugs are dispensed.

This article is for informational purposes only and does not constitute medical, legal, or reimbursement advice. Readers should consult state regulations and plan materials before making policy or treatment decisions.

Sources